Weight Watchers plans to sell Novo's obesity pill once it launches - report

[Weight-Loss Drug Wegovy Approved For Heart Health Under Medicare Despite Price]
Scott Olson/Getty Images News

WW International (WW [https://seekingalpha.com/symbol/WW]), popularly known as Weight Watchers, plans to sell Novo Nordisk's (NVO [https://seekingalpha.com/symbol/NVO]) weight loss drug Wegovy in pill form if it launches in the U.S. next year, _Reuters _reported.

"We have been working with Novo Nordisk ahead of time to support the launch of oral weight-loss medication," WW (WW [https://seekingalpha.com/symbol/WW]) CEO Tara Comonte told _Reuters_. "A lot of people don't want an injection. And the convenience of a pill is going to be huge."

WW (WW [https://seekingalpha.com/symbol/WW]) could retain more customers on its platform than telehealth rivals that push cheaper copies of GLP-1 drugs. This is because people are expected to switch to branded drugs once prices are lowered [https://seekingalpha.com/news/4518819-eli-lilly-novo-down-us-drug-pricing-deal] under a deal with the Trump administration.

Monthly prices of Novo's (NVO [https://seekingalpha.com/symbol/NVO]) Ozempic and Wegovy injections will fall from $1,000 and $1,350, respectively, to $350 on TrumpRx, which is set to launch in January.

The Wegovy pill is currently undergoing a speedier FDA review [https://seekingalpha.com/news/4517645-novo-nordisk-eli-lilly-oral-obesity-drugs-included-new-fda-priority-voucher-program]. If approved, starting doses of the pill will cost $149 a month.

"Anything that brings pricing down for these medications is good for Weight Watchers," Comonte said [https://www.reuters.com/business/healthcare-pharmaceuticals/weightwatchers-sell-novo-nordisks-wegovy-pill-after-2026-launch-2025-11-12/].

MORE ON WW INTERNATIONAL, NOVO NORDISK

* Novo Nordisk: Reliable Weigh-Loss Growth Story With More Upside Than Bears Admit [https://seekingalpha.com/article/4842886-novo-nordisk-stock-q3-significantly-undervalued]
* Novo Nordisk slashes Wegovy price in India as Lilly’s Mounjaro tops sales [https://seekingalpha.com/news/4520409-novo-nordisk-slashes-wegovy-price-india]
* WW targets $700M revenue for 2025 as GLP-1 demand accelerates [https://seekingalpha.com/news/4517892-ww-international-outlines-digital-overhaul-and-targets-700m-revenue-for-2025-as-glpminus-1]
* Weight Watchers offering weight loss drugs on Amazon Pharmacy [https://seekingalpha.com/news/4505629-weight-watchers-offering-weight-loss-drugs-on-amazon-pharmacy-shares-climb-10]